← Leaderboards
Rafal L Pawlinski
Univ Of North Carolina Chapel Hill
$8,739,544
Attributed
$18,290,437
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2011–25$2.5M$1.9M$1.3M$625K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,290,437 · 7
By mechanism
R01$10,721,985 · 6
U01$7,568,452 · 1
Top collaborators
- Nigel S Key11 shared
- Nigel Mackman5 shared
- Kenneth I Ataga4 shared
- Jian None Liu4 shared
- Ding Xu4 shared
- Evi X. Stavrou2 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Nigel S Key$14,906,926
Others in their field
Top investigators on “Mouse Model”
- Dennis R. Burton · Scripps Research Institute$280,661,242
- David Heimbrook · Leidos Biomedical Research, Inc.$84,491,283
- Kc Kent Lloyd · University Of California At Davis$74,285,556
- Alan F Horwitz · University Of Virginia Charlottesville$73,668,592
- Stanley B Prusiner · University Of California San Francisco$61,905,394
- Ed Lein · Allen Institute$59,425,748
Research focus
Mouse ModelCoagulation ProcessAttenuatedMediatingThrombinInflammationPreventPathway InteractionsGenerationsBlood VesselsLeadSickle Cell AnemiaNeutrophilOrganThromboplastinPrincipal InvestigatorCellsProgramsSickle CellEnvironmentResponseComplexChronicPlay
Grant awards (26)
Mechanisms of venous thrombosis and renal dysfunction in sickle trait$697,943
R01 · FY2025 · HL
Role of Factor XII in Thrombo-Inflammatory Complications of Sickle Cell Disease$696,975
R01 · FY2025 · HL · contact PI
Role of Factor XII in Thrombo-Inflammatory Complications of Sickle Cell Disease$724,727
R01 · FY2024 · HL · contact PI
Mechanisms of venous thrombosis and renal dysfunction in sickle trait$720,846
R01 · FY2024 · HL
Mechanism of sickle cell disease-specific venous thromboembolism$647,758
R01 · FY2024 · HL · contact PI
Mechanism of sickle cell disease-specific venous thromboembolism$660,978
R01 · FY2023 · HL · contact PI
Mechanism of sickle cell disease-specific venous thromboembolism$660,978
R01 · FY2022 · HL · contact PI
Mechanism of sickle cell disease-specific venous thromboembolism$673,465
R01 · FY2021 · HL · contact PI
In vitro synthesis of recombinant heparan sulfate$463,744
R01 · FY2021 · HL
Mechanisms of coagulation-dependent pathologies in sickle cell disease$388,750
R01 · FY2021 · HL · contact PI
In vitro synthesis of recombinant heparan sulfate$465,717
R01 · FY2020 · HL
Mechanisms of coagulation-dependent pathologies in sickle cell disease$388,750
R01 · FY2020 · HL · contact PI
In vitro synthesis of recombinant heparan sulfate$469,439
R01 · FY2019 · HL
Mechanisms of coagulation-dependent pathologies in sickle cell disease$388,750
R01 · FY2019 · HL · contact PI
In vitro synthesis of recombinant heparan sulfate$485,396
R01 · FY2018 · HL
Mechanisms of coagulation-dependent pathologies in sickle cell disease$388,750
R01 · FY2018 · HL · contact PI
Targeted Anticoagulant Therapy for Sickle Cell Disease$1,481,743
U01 · FY2017 · HL
Targeted Anticoagulant Therapy for Sickle Cell Disease$1,481,743
U01 · FY2016 · HL
Targeted Anticoagulant Therapy for Sickle Cell Disease$1,459,516
U01 · FY2015 · HL
The Role of Tissue Factor: FVIIa-PAR-2 Signaling in Heart Ischemia/Reperfusion$364,450
R01 · FY2015 · HL · contact PI
Targeted Anticoagulant Therapy for Sickle Cell Disease$1,452,109
U01 · FY2014 · HL
The Role of Tissue Factor: FVIIa-PAR-2 Signaling in Heart Ischemia/Reperfusion$362,600
R01 · FY2014 · HL · contact PI
Targeted Anticoagulant Therapy for Sickle Cell Disease$1,693,341
U01 · FY2013 · HL
The Role of Tissue Factor: FVIIa-PAR-2 Signaling in Heart Ischemia/Reperfusion$344,929
R01 · FY2013 · HL · contact PI
The Role of Tissue Factor: FVIIa-PAR-2 Signaling in Heart Ischemia/Reperfusion$362,800
R01 · FY2012 · HL · contact PI
The Role of Tissue Factor: FVIIa-PAR-2 Signaling in Heart Ischemia/Reperfusion$364,240
R01 · FY2011 · HL · contact PI